Rozanolixizumab
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Rozanolixizumab |
| DrugBank ID | DB14919 |
| Brand Names (EU) | Rystiggo |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 95.28% |
Approved Indication (EMA)
Rystiggo is indicated as an add-on to standard therapy for the treatment of generalised myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | bronchitis | 95.28% | DL |
| 2 | plasma cell myeloma | 95.05% | DL |
| 3 | indolent plasma cell myeloma | 94.73% | DL |
| 4 | hemoglobinopathy | 94.17% | DL |
| 5 | gastric carcinoma | 93.59% | DL |
| 6 | partial deletion of the short arm of chromosome 16 | 93.39% | DL |
| 7 | diffuse gastric adenocarcinoma | 93.36% | DL |
| 8 | beta-thalassemia with other manifestations | 93.13% | DL |
| 9 | hemolytic anemia due to glucophosphate isomerase deficiency | 92.75% | DL |
| 10 | pyruvate kinase deficiency of red cells | 92.56% | DL |
| 11 | severe nonproliferative diabetic retinopathy | 92.55% | DL |
| 12 | gastric linitis plastica | 92.29% | DL |
| 13 | diabetic retinopathy | 92.29% | DL |
| 14 | pyropoikilocytosis, hereditary | 92.10% | DL |
| 15 | gastric adenocarcinoma and proximal polyposis of the stomach | 91.92% | DL |
| 16 | Epstein-Barr virus-associated carcinoma | 91.89% | DL |
| 17 | carcinoma in situ of gastric cardia | 91.83% | DL |
| 18 | carcinoma in situ of gastric body | 91.81% | DL |
| 19 | gastric cardia adenocarcinoma | 91.81% | DL |
| 20 | Jeune syndrome situs inversus | 91.80% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.